Navigation Links
UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam
Date:12/3/2007

ATLANTA, Dec. 3 /PRNewswire/ -- UCB today announced data demonstrating that anti-epileptic drug (AED) brivaracetam, with the proposed trade name Rikelta(TM), administered as an adjunctive treatment in adults with refractory epilepsy with partial onset seizures, significantly reduced seizure frequency and had a side-effect profile comparable to placebo. The results of the two Phase IIb (Abstracts C.04 and 3.218), double-blind, randomized, parallel- group, placebo-controlled dose ranging studies were presented today as an oral platform presentation at the 61st annual meeting of the American Epilepsy Society.

"It is exciting to see the promising results that brivaracetam produced in this highly refractory population of epilepsy patients," said Jacqueline French, MD, lead study author and professor of neurology at New York University. "The development of novel anti-epilepsy drugs is vital to addressing the needs of treatment-resistant epilepsy patients. We look forward to seeing the results of our Phase III clinical research."

The two studies involved 365 patients, ages 16-65, with refractory partial onset seizures, which were uncontrolled despite treatment with one to two other AEDs. Patients in the first study (Abstract C.04) were randomized to receive 5 mg/day, 20 mg/day, 50 mg/day or placebo, administered twice-daily without titration over the seven week treatment period. The study found that brivaracetam reduced weekly seizure frequency over placebo by 9.8%, 14.9%, and 22.1% with doses of 5mg/day, 20 mg/day, and 50 mg/day, respectively, suggesting a dose response trend with brivaracetam 5 mg-50 mg/day.

An analysis of the study's secondary endpoints found that brivaracetam:

-- Reduced median seizure frequency from baseline by 29.9%, 42.6% and

53.1% for 5mg/day, 20mg/day and 50mg/day, respectively, compared with

21.7% for placebo.

-- Reduced weekly seizure frequency from baseline in 32.0%, 44.2% and


'/>"/>
SOURCE UCB, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013 The Drug Delivery Partnering Terms ... to the drug delivery partnering deals and agreements entered ... The report provides a detailed understanding and analysis of ... The majority of deals are discovery or development stage ... right to license the license drug delivery technology. These ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Senior drug regulatory ... on June 25 to discuss—for the first time in the ... getting drugs through the regulatory process in a timely manner. ... evaluation will share respective best practices and processes in drug ... Strait panel at the DIA 2013 49th Annual ...
(Date:6/18/2013)... Biomet hip lawsuit claims ... in a multidistrict litigation in U.S. District Court, Northern ... to court records, the litigation’s most recent status conference ... Court also convened a motions hearing and a tutorial ... Biomet hip replacement litigation. The proceeding’s next Status ...
(Date:6/18/2013)... Dallas, TX (PRWEB) June 18, 2013 ... Tebbetts, launched his new website, thebestbreast.com, showcasing his ... provides women with information about his surgical method ... , Outlined on his website, Dr. Tebbetts ... Unlike the traditional methods, Dr. Tebbetts’ method does ...
(Date:6/18/2013)... using technology developed at Case Western Reserve University,s ... of Engineering, has made available avatarsvirtual patientsto train ... and others training to evaluate speech-language disorders to ... on the trainee, because a diagnosis doesn,t have ... , Graduate students studying to become speech-language pathologists ...
Breaking Medicine News(10 mins):Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3Health News:Internationally Acclaimed Breast Augmentation Expert Announces the Launch of His New Website 2Health News:SimuCase avatars advance speech-language pathology training 2
... RATON, Fla., Sept. 26 Biomedtex Inc.,(Pink Sheets: ... company, announced today that A. Marc Rocca, 42, ... The Company,s mission is to identify, evaluate ... and healthcare solutions, and then,seek to capture and ...
... Consider Proposals and Variations, LOS ANGELES, ... ISCR) a leading e-health Wi-Fi PDA technology ... DME and EMR applications,and the distributor of ... surgical products, announced today that its Board ...
... North America in Deal Valued at up ... to $185 ... 26, NPS Pharmaceuticals, Inc. (Nasdaq: NPSP ) and,Nycomed announced ... to Nycomed the rights to develop and commercialize,GATTEX(TM) (teduglutide) outside ...
... ultrasound-guided fine needle to biopsy lymph nodes could spare ... to undergo unnecessary and sometimes unpleasant surgery to verify ... , In a study presented today (Wednesday) at the ... that the less invasive technique produced a false positive ...
... Barcelona, Spain: New research has yielded a clearer picture ... the treatment of colon cancer, bringing closer the day ... spared it, while those that will, get the more ... other solid tumours, doctors plan treatment of colon cancer ...
... to use for older people is the focus of a ... in funding in the latest round of the Australian Research ... design researcher Dr Thea Blackler, is one of 24 projects ... announcement tops off a successful week for QUT research, with ...
Cached Medicine News:Health News:InstaCare Corp. Reviewing M&A Plans 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 3Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 4Health News:Less invasive lymph node biopsy method could spare thousands unnecessary operations 2Health News:Study makes progress in zoning in on biomarkers for better colon cancer treatment 2
(Date:6/18/2013)... -- , Safinamide significantly improves responder ... add-on to levodopa Safinamide is associated ... fluctuating PD patients as add-on to levodopa ... a research and development company focused on novel ... S.p.A., a pharmaceutical company strongly committed to the ...
(Date:6/18/2013)... 18, 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... announced today that VPII Escrow Corp., a newly formed ... its offer of approximately $3.2 billion aggregate principal amount ... be due in 2021 and in 2023, with final ... to use the net proceeds from the offering, together ...
(Date:6/18/2013)... June 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... on the development and commercialization of novel bile acid ... pricing of an underwritten public offering of 1,730,000 shares ... of $33.01 per share.  In addition, Intercept has granted ... an additional 259,500 shares of common stock. ...
Breaking Medicine Technology:Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... 1, 2011 Reportlinker.com announces that a new market ... Pen Injectors http://www.reportlinker.com/p0369406/Pen-Injectors.html ... increasing number of drugs in pre-filled disposable cartridges and ... the expense of other drug delivery methods such as ...
... Feb. 1, 2011 Reportlinker.com announces that a ... catalogue: Epoetin alfa - Comprehensive ... Eliminate unnecessary risk with the industry ... Developer is a regularly updated, professional patent search ...
Cached Medicine Technology:Reportlinker Adds Epoetin alfa - Comprehensive patent search 2Reportlinker Adds Epoetin alfa - Comprehensive patent search 3Reportlinker Adds Epoetin alfa - Comprehensive patent search 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: